<DOC>
	<DOCNO>NCT02542436</DOCNO>
	<brief_summary>This study focus participant United Kingdom ( UK ) collect local data effectiveness safety bevacizumab ( Avastin ) treatment metastatic colorectal cancer normal clinical use .</brief_summary>
	<brief_title>Avastin ( Bevacizumab ) Treatment Metastatic Colorectal Cancer Normal Clinical Use UK Population</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Have diagnose metastatic colorectal cancer ( mCRC ) Have Performance Status ( PS ) 02 , accord Eastern Cooperative Oncology Group ( ECOG ) criterion initiation bevacizumab treatment Be chemotherapynaive diagnosis mCRC relapse 12 month receive adjuvant chemotherapy early stage colorectal cancer Have receive standard fluoropyrimidinebased chemotherapy firstline treatment mCRC without bevacizumab Have sufficient medical record available assessment eligibility Christie Hospital National Health Service ( NHS ) Trust , Manchester , United Kingdom For Cohort 1 ( post CDF funding availability ) : patient 20102013 receive bevacizumab firstline chemotherapy For Cohort 2 ( pre Cancer Drugs Fund [ CDF ] fund availability ) : patient propensity match cohort 1 20052008 receive bevacizumab firstline chemotherapy Subjects metastatic colorectal cancer , receive bevacizumab via clinical trial Subjects metastatic colorectal cancer , whose medical record complete enough confirm eligibility study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>